Related Experiment Video

Updated: Jul 25, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Low-dose methotrexate as a risk factor for Pneumocystis carinii pneumonia

S Krebs1, R B Gibbons

  • 1Department of Medicine, Saint Joseph Hospital, Denver, CO 80218, USA.

Military Medicine
|January 1, 1996
PubMed

Insights

Low-dose methotrexate, used for rheumatoid arthritis, can increase the risk of Pneumocystis pneumonia. This risk is higher with concurrent use of corticosteroids or NSAIDs, or in patients with kidney issues.

Area of Science:

  • Rheumatology
  • Infectious Diseases
  • Pharmacology

Background:

  • Low-dose methotrexate is a standard treatment for rheumatoid arthritis and other rheumatic conditions.
  • Methotrexate is generally well-tolerated with infrequent adverse effects compared to other immunosuppressants.
  • Pneumocystis pneumonia (PCP) typically affects severely immunocompromised individuals, such as those with AIDS or undergoing chemotherapy.

Observation:

  • Pneumocystis pneumonia has been observed in patients treated with low-dose methotrexate.
  • This opportunistic infection can occur even when methotrexate is used at low doses.
  • Risk factors include concurrent use of corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and renal impairment.

Findings:

  • The study reviewed 11 cases of Pneumocystis pneumonia in patients on low-dose methotrexate.
  • These cases highlight a potential association between low-dose methotrexate and PCP development.
  • Concurrent medications and patient comorbidities appear to influence the risk.

Implications:

  • Clinicians should be aware of the potential for PCP in patients receiving low-dose methotrexate, especially those with risk factors.
  • Careful monitoring for respiratory symptoms is warranted in this patient population.
  • Further research may be needed to fully elucidate the mechanisms and refine risk stratification.

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...